The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
August 7, 2023
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)
August 7, 2023 (Issue: 1682)
Glofitamab-gxbm (Columvi – Genentech), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for IV treatment of
relapsed or refractory diffuse large B-cell lymphoma
(DLBCL), not otherwise specified, or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.